Found 195 clinical trials
1 march 4
This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …
- 0 views
- 19 Feb, 2024
- 1 location
A081801 / RLUN20119 / ALCHEMIST-IO (ACCIO) / Yuhchyau Chen
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and …
- 0 views
- 19 Feb, 2024
- 1 location
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
Three approaches to improve transplant outcome will be studied: Comparing the new pre-transplant consolidation therapy vyxeos with the standard consolidation therapy Comparing new conditioning therapies in patients under the age of 55 years Comparing new conditioning therapies in patients aged 55 and over All patients will be followed up for …
- 0 views
- 19 Feb, 2024
Role of Lymphnode Dissection in Men With Prostate Cancer Treated With Radical Prostatectomy
Therefore, the aim of this study is to evaluate whether the removal of the lymph nodes during prostatectomy positively influences the course of the disease in patients with intermediate risk prostate cancer, or if the lymph node dissection does not have any influence on the recurrence of the disease and …
- 0 views
- 19 Feb, 2024
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.
- 0 views
- 19 Feb, 2024
Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus
Aim To investigate the effect of sentinel lymph node (SLN) sampling on the prognosis of patients with middle-high risk endometrial cancer obviously confined to the uterus before surgery.
- 0 views
- 19 Feb, 2024
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that radiotherapy with reduced dose could significantly reduce the incidence of radiotherapy toxicities, improve the quality of life of patients while ensuring the tumor control rates for NPC patients staged as II-III who are sensitive to induction chemotherapy (imaging evaluation …
- 6 views
- 19 Feb, 2024
Randomised Evaluation of COVID-19 Therapy
RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent plasma or Tocilizumab prevents death in patients with COVID-19.
- 0 views
- 19 Feb, 2024
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
- 0 views
- 19 Feb, 2024
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …
- 0 views
- 19 Feb, 2024